Comment on “What’s Missing in Diabetes Treatment? A Novel Agent, Finerenone?”

Finerenone


Abstract views: 60 / PDF downloads: 42

Authors

DOI:

https://doi.org/10.5281/zenodo.17454

Abstract

Letter to Editor - No Abstract

References

Öztürk İ, Yıldırım S, Polat M. What’s Missing In Diabetes Treatment? A Novel Agent Finerenone? Diabetic Nephropathy and Finerenone. J Eur Intl Med Prof. 2025;3(2):89–95. https://doi.org/10.5281/zenodo.15065667

Vaduganathan M, Claggett BL, Kulac IJ, et al. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2025;151(2):149-158. doi:10.1161/CIRCULATIONAHA.124.072055

Butt JH, Jhund PS, Henderson AD, et al. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025;13(2):107-118. doi:10.1016/S2213-8587(24)00309-7

Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. doi:10.1056/NEJMoa2410659

Downloads

Published

2025-10-27

How to Cite

Akgül, A., & Aylı, B. I. (2025). Comment on “What’s Missing in Diabetes Treatment? A Novel Agent, Finerenone?”: Finerenone. Journal of European Internal Medicine Professionals, 3(4), 178–179. https://doi.org/10.5281/zenodo.17454

Issue

Vol. 3 No. 4 (2025): J Eur Int Med Prof

Section

Letter to Editor

Categories

License

Copyright (c) 2025 Arzu Akgül, Berrak Itır Aylı

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.